J&J's 2025 drug sales forecast should not be tripping up inv

Johnson & Johnson (JNJ) reports a strong first quarter, with sales up more than 5.5% and earnings eking out an annual increase.

Related Keywords

China , Japan , Joseph Wolk , Jj Pharma Medtech , Jim Cramer , Abiomed , Jim Cramer Charitable , Johnson , Wall Street , Consumer Looking , Tech Strength , Allocation Management , Dividend King , Charitable Trust , Health Care Industry , Dividends , Earnings , Johnson Amp , Breaking News Markets , Markets , Investment Strategy , Club Earnings , Business News ,